Amsalog

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205769

CAS#: 80841-48-1 (isethionate)

Description: Asulacrine, also known as CI-921; NSC-343499; SN-21407, is the isethionate salt of an amsacrine analogue with antineoplastic properties. Asulacrine inhibits the enzyme topoisomerase ll, thereby blocking DNA replication and RNA and protein synthesis.


Chemical Structure

img
Amsalog
CAS# 80841-48-1 (isethionate)

Theoretical Analysis

MedKoo Cat#: 205769
Name: Amsalog
CAS#: 80841-48-1 (isethionate)
Chemical Formula: C26H30N4O7S2
Exact Mass:
Molecular Weight: 574.669
Elemental Analysis: C, 54.34; H, 5.26; N, 9.75; O, 19.49; S, 11.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Amsalog; Asulacrine isethionate; CI921; CI-921; CI 921; NSC-343499; SN-21407; NSC343499; SN21407.

IUPAC/Chemical Name: 9-((2-methoxy-4-(methylsulfonamido)phenyl)amino)-N,5-dimethylacridine-4-carboxamide ethanesulfonate

InChi Key: LCWHRDYEJGSWEV-UHFFFAOYSA-N

InChi Code: InChI=1S/C24H24N4O4S.C2H6O3S/c1-14-7-5-8-16-21(14)27-23-17(9-6-10-18(23)24(29)25-2)22(16)26-19-12-11-15(13-20(19)32-3)28-33(4,30)31;1-2-6(3,4)5/h5-13,28H,1-4H3,(H,25,29)(H,26,27);2H2,1H3,(H,3,4,5)

SMILES Code: O=C(C1=CC=CC2=C(NC3=CC=C(NS(=O)(C)=O)C=C3OC)C4=CC=CC(C)=C4N=C12)NC.CCS(=O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 574.669 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fyfe D, Raynaud F, Langley RE, Newell DR, Halbert G, Gardner C, Clayton K, Woll PJ, Judson I, Carmichael J. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation. Cancer Chemother Pharmacol. 2002 Jan;49(1):1-6. PubMed PMID: 11855748.

2: Fyfe D, Price C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC, Carmichael J; Cancer Research Campaing Phase I/II Trials Committee. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule. Cancer Chemother Pharmacol. 2001 Apr;47(4):333-7. PubMed PMID: 11345650.

3: Elliott W, Howard C, Roberts B, Hook K, Vincent P, Corbett T, Leopold W. Enhanced therapeutic effect of amsalog (CI-921) in combination with cisplatin in vitro and in vivo. Oncol Rep. 1996 Nov;3(6):1153-9. PubMed PMID: 21594529.

4: Sklarin NT, Wiernik PH, Grove WR, Benson L, Mittelman A, Maroun JA, Stewart JA, Robert F, Doroshow JH, Rosen PJ, et al. A phase II trial of CI-921 in advanced malignancies. Invest New Drugs. 1992 Nov;10(4):309-12. PubMed PMID: 1487405.

5: Robertson IG, Palmer BD, Paxton JW, Shaw GJ. Differences in the metabolism of the antitumour agents amsacrine and its derivative CI-921 in rat and mouse. Xenobiotica. 1992 Jun;22(6):657-69. PubMed PMID: 1441589.

6: Henck JW, Brown SL, Anderson JA. Developmental toxicity of CI-921, an anilinoacridine antitumor agent. Fundam Appl Toxicol. 1992 Feb;18(2):211-20. PubMed PMID: 1601220.

7: Harvey VJ, Hardy JR, Smith S, Grove W, Baguley BC. Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer. Eur J Cancer. 1991;27(12):1617-20. PubMed PMID: 1664218.

8: Paxton JW, Kim SN, Whitfield LR. Pharmacokinetic and toxicity scaling of the antitumor agents amsacrine and CI-921, a new analogue, in mice, rats, rabbits, dogs, and humans. Cancer Res. 1990 May 1;50(9):2692-7. PubMed PMID: 2328494.

9: Kestell P, Paxton JW, Evans PC, Young D, Jurlina JL, Robertson IG, Baguley BC. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Cancer Res. 1990 Feb 1;50(3):503-8. PubMed PMID: 2297692.

10: Ching LM, Finlay GJ, Joseph WR, Baguley BC. Comparison of the cytotoxicity of amsacrine and its analogue CI-921 against cultured human and mouse bone marrow tumour cells. Eur J Cancer. 1990 Jan;26(1):49-54. PubMed PMID: 2138478.



Additional Information

Related CAS#
80841-47-0 (Asulacrine)
80841-48-1 (Asulacrine isethionate)